WASHINGTON, D.C. (February 19, 2004) - This year's BIO CEO & Investor Conference features 39 panel discussions, including a new series of Therapeutic & Technology Focus Sessions, in addition to the event's popular plenary sessions and Business Roundtables. All told, executives, investors and journalists attending the conference will have the opportunity to hear from more than 100 leading experts on therapeutic and technology developments, business issues and industry trends.
The BIO CEO & Investor Conference - the largest biotechnology industry-run investor event in the world - runs Feb. 23 - 25 at the Waldorf=Astoria Hotel in New York City. Details are posted at www.bio.org/ceo.
"This is our strongest program ever, both in terms of quantity and quality," said Morrie Ruffin, BIO's vice president for business development. "This year, we've not only lined up an outstanding group of biotechnology leaders, but we've also gone outside the industry itself to bring together an impressive array of experts from the nation's leading medical institutions, government agencies, universities and foundations."
Each Therapeutic & Technology Focus Session will bring together clinical, medical and industry experts in addition to representatives of five biotechnology companies. The sessions cover trends in drug discovery and development, including RNAi, biomarkers and pathway biology, as well as targeted disease areas, including rheumatoid arthritis, cancer, infectious diseases, asthma and allergies, stroke, diabetes and liver disease. A complete listing of Focus Sessions is posted at http://www2.bio.org/hermes/ceo/presenters/index.asp?page=focus.
The Business Roundtables will delve into issues critical to biotech CEOs, such as increasing shareholder value, M&A and licensing strategies, new disclosure rules, emerging business models, commercialization and product reimbursement strategies and current investment trends. A complete listing of Business Roundtables is posted at http://www2.bio.org/hermes/ceo/roundtable/.
Speakers include: Scott Gottlieb, M.D., Office of the Commissioner, U.S. Food and Drug Administration; David K. Elder, Director of Enforcement, U.S. Food and Drug Administration; Jeffrey P. Riedler, Assistant Director, Office of Health Care and Insurance, Division of Corporate Finance, U.S. Securities and Exchange Commission; Howard Fillit, M.D., Institute for the Study of Aging; Paul B. Iannini, M.D., FACP, Danbury Hospital and Yale University; Lanny J. Rosenwasser, M.D., National Jewish Medical and Research Center in Denver; Clyde Yancy, M.D., University of Texas Southwestern, John Urquhart, M.D., FRCPE, FAAAS, FISPE, University of California, San Francisco; Donald C. Manning, M.D., Ph.D., The University of Virginia Health Sciences Center; Dr. Pamela Davis, Case Western Reserve University; Ira M. Jacobsen, M.D., Cornell University; Scott L. Friedman, M.D., Division of Liver Diseases, Mount Sinai School of Medicine; Alan P. Brownstein, President and Chief Executive Officer, American Liver Foundation; Dr. Jill Buyon, NYU Medical Center, Hospital for Joint Diseases; Brian Annex, M.D., Duke University; Carmen A. Puliafito, M.D., M.B.A., University of Miami School of Medicine, H. Lee Sweeney, Ph.D., University of Pennsylvania; Anna C. Ferrari, M.D., Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine; Dr. Gerald Bernstein, Beth Israel Deaconess Medical Center; Jerald Sadoff, Aeras Global TB Foundation; and Kenneth Kosik, M.D., Brigham and Women's Hospital.
Registration is complimentary for credentialed news media and investors. Please note on-site media registration will be open only to reporters and editors with valid media credentials working full-time for print or broadcast news organizations.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.